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Abstract 
Sarcomas are a rare occurrence accounting
for roughly 1% of all cancer cases reported. Of
these, 9-18% will be identified as liposarcoma.
Overall, only 4-9% of all liposarcomas occur in
the head and neck region. As such, it is a rare
event  to  see  a  primary  liposarcoma  of  the
aerodigestive tract. These tumors are typically
misdiagnosed  secondary  to  their  indolent,
asymptomatic  course  and  similarities  in
appearance to other benign lesions. An under-
standing of these lesions will help clinicians
appropriately manage their patients. We pres-
ent a case of a 60-year male with a primary
supraglottic myxoid liposarcoma, and provide
relevant information about liposarcomas.
Introduction
Sarcomas are malignant neoplasms arising
from connective tissue. They represent rough-
ly 1% of all cancer cases reported. One subtype
of sarcoma is liposarcoma. This type of sarco-
ma  represents  anywhere  from  9-18%  of  all
reported sarcoma cases, with only 4-9% occur-
ring in the head and neck region.
1,2 Although
more common in other areas, it is rarely found
in the aerodigestive tract.
2-8 We present a case
of a primary liposarcoma of the supraglottic
larynx in an adult male. 
Case Report
A 60-year old male presented to our clinic
with  complaints  of  progressive  dysphagia  to
solids and liquids along with hoarseness and
occasional choking episodes. He had been ini-
tially  evaluated  by  a  gastroenterologist  who
performed  an  esophagram  that  showed  full-
ness in the hypopharynx but normal motility
and  no  mucosal  irregularities.  Upon  further
questioning,  the  patient  revealed  having
undergone  removal  of  a  benign  fibrolipoma
from his cervical esophagus in 2002. He had a
history of smoking but denied alcohol or drug
use. Upon examination, he was found to have
a polypoid lesion involving his left arytenoid.
His  true  vocal  cords  were  mobile,  and  the
remainder of the head and neck examination
was unremarkable. The patient was taken to
the  operating  room  for  biopsy.  Pathological
examination revealed a benign fibroepithelial
polyp. Two months later, the patient presented
with worsening dysphagia, hoarseness, dysp-
nea,  and  inspiratory  stridor.  Upon  fiberoptic
laryngoscopy, he was found to have multiple
polypoid lesions involving the left arytenoid,
left aryepiglottic fold, and post-cricoid region
(Figure 1).
The lesions were now causing significant
airway obstruction, and so the patient under-
went  tracheostomy  with  further  biopsies.
Although  pathological  evaluation  revealed
benign squamous tissue with chronic inflam-
mation, a subsequent CT scan was of greater
concern. This revealed a 3.5¥3.3¥3.2 cm het-
erogeneous laryngeal mass that occluded the
airway and invaded through the thyroid carti-
lage (Figure 2). 
Therefore, the patient was taken back to the
operating  room,  and  larger  biopsies  were
obtained using a CO2 laser, which demonstrat-
ed  a  liposarcoma.  The  patient  subsequently
underwent a total laryngectomy, partial pha-
ryngectomy and reconstruction with an antero-
lateral thigh free flap. Gross examination of
the laryngectomy specimen revealed a submu-
cosal, yellowish-white polypoid mass measur-
ing 6.2¥6¥2.5 cm arising from the left supra-
glottic  region  and  partially  obliterating  the
glottis.  Microscopic  examination  showed
mature  adipose  tissue  with  occasional
lipoblasts as well as focal areas of myxoid dif-
ferentiation  containing  atypical  spindle  cells
with large, hyperchromatic nuclei, consistent
with a well-differentiated myxoid liposarcoma
(Figure 3).
The patient has remained free of neoplastic
recurrence for over a year and a half.
Discussion
A liposarcoma is a malignant mesenchymal
neoplasm  arising  from  deep-seated  adipose
tissue. Although rare, there have been reports
of these neoplasms arising from pre-existing
lipomas.
9 Liposarcomas are the second most
common soft tissue sarcoma. They represent
roughly  9-18%  of  all  sarcomas,  and  tend  to
have a high predilection for the extremities
and retroperitoneum.
1,2 Overall, only 4-9% of all
liposarcomas  occur  in  the  head  and  neck
region.
2 Roughly 80% of these neoplasms occur
in adults with a peak incidence around 40-60
years of age.
10 Their occurrence in children is
very rare accounting for less than 5% of all soft
tissue sarcoma cases in children.
9,11
Liposarcomas  are  classified  by  their
histopathological  appearance.  There  are  five
recognized subtypes: well-differentiated, myx-
oid, round-cell, dedifferentiated, and pleomor-
phic. The myxoid subtype is the most common
subtype, representing anywhere from 45-55%
of cases. These tumors are considered low to
intermediate  grade.  The  well-differentiated
subtype is the second most common subtype
and represents 30-40% of cases. It is the lowest
grade of all subtypes, and as such, tends to
carry a better prognosis. The round-cell sub-
type is considered the high-grade counterpart
of the myxoid subtype and typically represents
15% of all cases of liposarcomas. The dediffer-
entiated subtype is believed to arise from long
standing  or  recurrent  well-differentiated
tumors. Depending on the amount of dediffer-
entiation, these can be intermediate or high
grade. The pleomorphic subtype is the highest
grade subtype, and caries the worst prognosis.
Fortunately,  this  subtype  is  rare,  accounting
for only 5% of all liposarcoma cases.
1,2,9-11
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is  believed  to  involve  various  chromosomal
abnormalities. The well-differentiated subtype
is known to be associated with abnormalities
of  1q  and  12q13-15,  while  the  myxoid  and
round-cell  subtypes  tend  to  have  transloca-
tions. The most common of these transloca-
tions is the t(12;16)(q13;p11.2) translocation.
This  involves  the  fusion  of  the  CHOP gene
(transcription  gene  that  regulates  adipocyte
differentiation) on chromosome 12 with the
TLS gene on chromosome 16.
10,11
The diagnosis of a liposarcoma is typically
delayed  secondary  to  its  indolent,  asympto-
matic  course.  Upon  gross  inspection,  these
tumors appear very similar to those of lipomas.
However, there are details that help to differ-
entiate the two. Liposarcomas tend to be more
fixed to the underlying tissue, less compressi-
ble, and firmer to palpation. They also tend to
be less lobulated and less yellow in color when
compared to lipomas.
1,9,11
There  are  multiple  imagining  modalities
available  to  aid  the  clinician  in  diagnosing
liposarcomas.  Of  these,  the  most  commonly
utilized are the MRI and CT scans. The MRI is
probably the most useful since it may reveal
characteristics of the tumor that are sugges-
tive  of  malignancy.  On  MRI,  liposarcomas
appear well-circumscribed and lobulated with
thick, fibrous septae and nodularity. In addi-
tion to these findings, the presence of hemor-
rhage, edema, and areas of necrosis may also
be noted, which may hint at malignancy. The
level of enhancement can also be utilized in
assessing these tumors. Low-grade liposarco-
mas tend to exhibit faint enhancement follow-
ing contrast while their high-grade counter-
parts typically enhance very well with contrast.
The amount of heterogeneity is also important
as it can aid in determining the grade of the
tumor.  Well-differentiated  liposarcomas  typi-
cally appear homogeneous while myxoid types
exhibit slight heterogeneity. The dedifferenti-
ated, round cell, and pleomorphic types tend to
exhibit moderate to marked heterogeneity.
1,9,11
The gold standard in diagnosing a liposarco-
ma  remains  the  biopsy.  This  can  be  done
through fine needle aspiration and incisional
or excisional biopsy. Some recommend avoid-
ance of excisional biopsy in suspected cases of
liposarcoma as it may negatively affect treat-
ment planning.
1,9-11
While each subtype has its own pathological
characteristics, the key to the diagnosis is the
presence of the lipoblast.
5,12 Our patient’s type
is  a  myxoid  liposarcoma.  These  tumors  are
characterized by three main features. The first
is the presence of multiple lipoblasts in various
stages of development. The second feature is
the presence of a delicate plexiform capillary
network.  Finally,  the  stromal  matrix  is  com-
posed  of  hyaluronidase-sensitive  acid  muco  -
poly  saccharides. The least cellular forms are
considered lower grade tumors, and typically
contain more spindle-shaped cells. The high
cellular forms are considered high grade, and
typically  exhibit  an  abundance  of  round
cells.
1,9,11,13
Case Report
Figure 1. Image obtained by flexible laryn-
goscopy showing the multiple supraglottic
polypoid lesions (arrows) and thickening
of the left aryepiglottic fold (arrowhead).
Figure 2. Axial CT images with contrast showing the laryngeal lesion invading and
destroying the thyroid cartilage (arrows) while also significantly narrowing the patient’s
airway (arrowheads).
Figure 3. (Top panel) Submucosal polypoid liposarcoma (arrows) arising from the left
supraglottic region. (Bottom left) Well-differentiated liposarcoma with an area of myx-
oid differentiation. (Bottom right) (H&E, x40). (Bottom middle) Myxoid differentiation
(H&E, x200). (Bottom right) Lipoblasts (arrows) with vacuolated cytoplasm and atypi-
cal nuclei (H&E, x600).[page 114] [Rare Tumors 2010; 2:e41]
The mainstay of treatment for liposarcomas
is surgical excision. This is performed through
wide or radical excision of the tumor. Since a
positive  margin  is  strongly  correlated  with
tumor recurrence, it is extremely important to
obtain tumor free margins. The rate of recur-
rence has been reported to increase from 17%
to 80% with incomplete excision. There is no
consensus  on  the  amount  of  free  margin
required,  but  some  surgeons  recommend
obtaining at least two centimeters of free mar-
gin.  Elective  neck  dissection  is  not  recom-
mended  as  regional  nodal  metastasis  is
extremely rare.
1,10-14
The  use  of  adjunctive  treatments  in  the
overall treatment of liposarcoma remains con-
troversial. The most common adjunctive treat-
ment used is radiotherapy. A number of stud-
ies have shown improved local control and sur-
vival  rates  when  radiotherapy  is  combined
with surgery. Spiro et al. examined multiple
studies involved with the treatment of all soft
tissue sarcomas. When specifically examining
liposarcoma, they found an 85-90% local con-
trol  rate  when  surgery  was  combined  with
radiotherapy. They also noted a difference in
local control rates based on the dose and deliv-
ery of the radiotherapy. More specifically, they
found a 44% local control rate when the radia-
tion dose was 64 Gy or more compared to a 15%
local control rate when the dose was less than
64 Gy. They also found a local control rate of
65% when the radiation was delivered utilizing
the intraoperative electron beam method ver-
sus  a  20%  local  control  rate  when  external
beam radiation was utilized.
14 In another study,
Evans examined 55 cases of soft tissue liposar-
coma and found improved local control rates
when radiotherapy was combined with surgery
in the treatment of liposarcoma. When exam-
ining the myxoid subtype of liposarcoma, he
noted a local failure in 14 of 18 cases treated
with  surgery  alone,  but  only  one  of  8  cases
when surgery was combined with radiothera-
py. Overall, however, he did not find a survival
benefit  with  the  addition  of  radiotherapy.
15
Longhi et al. examined 122 cases of soft tissue
liposarcoma and found that when radiotherapy
(40-45 Gy) was given following surgical exci-
sion, the 5-year survival rate improved to 92%,
up  from  80%  found  with  surgical  excision
alone. Also of interest from this study was that
the timing of radiotherapy made a difference
in the overall survival rate. When radiotherapy
was given pre-operatively, the 5-year survival
rate was 81% compared to 92% when the radio-
therapy was given post-operatively.
16 Golledge
et  al. examined  76  cases  of  head  and  neck
liposarcoma and found an 83% 5-year survival
rate with surgery alone versus a 63% 5-year
survival rate when surgery was combined with
radiotherapy. However, it was noted that radio-
therapy was only used in cases of high-grade
liposarcoma (round cell and pleomorphic sub-
types specifically) and not in any cases of low-
grade  liposarcoma.
3 Currently,  chemotherapy
is typically not used in the treatment of liposar-
coma given its lack of sensitivity to chemother-
apeutic agents.
1,9,11,14,16 In the study by Longhi et
al. there was no improvement in survival when
chemotherapy was added to the treatment reg-
imen;  79%  5-year  survival  rate  in  the
chemotherapy group versus 80% in the surgery
alone group.
16 It is surmised that the myxoid
subtype of liposarcoma may actually be more
chemosensitive than other subtypes of liposar-
coma, but further study is needed to substanti-
ate this.
14 The overall rate of distant metastasis
in cases of liposarcoma is 30%.
2 The likelihood
that a liposarcoma will metastasize is related
to  its  subtype,  and  as  such,  its  grade.
Metastasis  occurs  more  commonly  among
pleomorphic, round cell, and dedifferentiated
subtypes, and typically involves the lungs and
liver.
2,13,14 The overall prognosis is determined
by multiple factors, but most importantly histo-
logical type and extent of surgical control. The
5-year survival rate is 85-100% for well-differ-
entiated liposarcoma, 77-95% for the myxoid
subtype, 21-45% for the pleomorphic subtype,
and roughly 30% for the dedifferentiated sub-
type.
2,11,12 Size may also play a role in prognosis
as some studies have found that smaller tumor
size  is  associated  with  decreased  rates  of
recurrence  and  increased  survival  rates.
5,6
However, others have found no statistically sig-
nificant  correlation  between  the  size  of  the
tumor and the overall prognosis.
1,4
Conclusions
Liposarcoma of the head and neck remains a
rare occurrence, especially as a primary tumor
of the aerodigestive tract. These tumors are typ-
ically misdiagnosed secondary to their indolent
course and similarities in appearance to more
commonly  encountered  benign  lesions.  Once
indentified, these tumors are best treated with
wide surgical excision with a consideration for
adjuvant radiotherapy. The use of chemothera-
py remains controversial, and as such, further
study is required to determine its effectiveness
in the treatment of liposarcomas.
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